Table 1.
Volatile organic compounds in digestive neoplasia: articles included.
No | Author | Pathology | VOCs Proposed as Biomarkers |
---|---|---|---|
1 | Hartwig et al., 2017 [11] | Oral squamous cell carcinoma (OSCC) |
Signature of eight VOCs for OSCC
VOCs decreased after cancer surgery:
|
2 | Bouza et al., 2017 [13] | Oral squamous cell carcinoma (OSCC) |
VOCs possible biomarkers for OSCC:
|
3 | Adam et al., 2019 [14] | Esophagogastric cancer (OGC) |
VFAs increased in mixed breath in esophagogastric cancer:
|
4 | Markar et al., 2018 [15] | Esophagogastric cancer (OGC) |
Five-VOCs diagnostic predictive model:
increased
|
5 | Chin et al., 2018 [10] | Esophagogastric cancer (OGC) |
VOCs predominantly expressed:
|
6 | Zou et al., 2016 [16] | Esophageal cancer (EC) |
Five ions decreased:
Thioethanol
1, 3-cycloheptadiene,
P-xylene O-xylene M-xylene benzaldehyde
Ethylene oxide Two ions increased:
|
7 | Kumar et al., 2015 [9] | Esophagogastric cancer (OGC) Esophageal cancer Gastric adenocarcinoma |
VOCs significantly increased in both cancers:
|
8 | Kumar et al., 2013 [17] | Esophagogastric cancer (OGC) |
Significantly increased in esophageal cancer:
|
9 | Chen et al., 2016 [18] | Gastric cancer (GC) |
> 80% of healthy, but barely existed in EGC:
|
10 | Xu et al., 2013 [19] | Gastric cancer (GC) |
VOCs increased in gastric cancer:
|
11 | Amal et al., 2015 [20] | Gastric cancer (GC) Gastric intestinal metaplasia Peptic ulcer disease |
VOCs with significant difference between groups:
|
12 | De Vietro et al., 2020 [21] | Colorectal cancer |
VOCs increased in colorectal cancer:
|
13 | Peng et al., 2010 [22] | Cancers, including colon cancer |
VOCs increased in colon cancer:
|
14 | Markar et al.,2018 [23] | Pancreatic cancer |
VOCs increased in pancreatic cancer:
|
15 | Princivalle et al., 2018 [24] | Pancreatic ductal adenocarcinoma (PDA) |
VOCs increased in PDA:
|
16 | Qin et al., 2010 [25] | Hepatocellular carcinoma (HCC) Hepatitis Cirrhosis |
VOCs increased in HHC:
|
Abbreviations: GC-MS—gas chromatography mass spectrometry; OLGIM—operative link on gastric intestinal metaplasia; OSCC—oral squamous cell carcinoma; OGC—esophagogastric cancer; MIM—multiple ion monitoring; PUD—peptic ulcer disease; VFAs—volatile fatty acids; VOCs—volatile organic compounds; SIFT-MS—selected ion flow tube mass spectrometry; SPME—gas chromatography mass spectrometry coupled with solid phase microextraction.